Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when RGNX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsREGENXBIO shareholders reject executive stock option exchange, approve program for staff
Filed June 3, 2026 · Period ending May 29, 2026 · ~1 min read
Key Changes
-
medium
Shareholders voted down a stock option exchange program for executives (21M against vs 14M for), signaling concern about executive compensation practices while approving a similar program for non-executive employees.
Item 5.07: Voting Results verify on EDGAR → -
medium
Company launched stock option exchange for non-executives (June 3-July 1), allowing employees to swap options with exercise prices at or above $18 for fewer new options at current market price, indicating stock has traded below $18.
Item 8.01: Exchange Program verify on EDGAR → -
low
Three Class II directors re-elected to serve until 2029: Jean Bennett, Jerry Karabelas, and Daniel Tassé, all receiving majority shareholder support in routine annual meeting vote.
Item 5.07: Director Elections verify on EDGAR → -
low
Management expects the option exchange program to have minimal impact on stock compensation expense, suggesting accounting treatment is structured to avoid material charges.
Item 8.01: Expense Impact verify on EDGAR →
Summary
REGENXBIO's annual meeting revealed a notable shareholder split on compensation practices. While investors approved a stock option exchange program for non-executive employees, they decisively rejected a similar program for executives by a 60-40 margin. This suggests shareholders are willing to support retention tools for staff but want to hold the line on executive pay, particularly given the stock's performance.
The approved exchange program, now live through July 1, targets options with exercise prices at or above $18—a threshold that confirms the stock has been trading underwater relative to past grants. Employees can swap these out-of-the-money options for fewer new ones priced at current market value.
The company says this won't materially increase compensation expense, but it does signal retention concerns when equity incentives lose their motivational power. Retail holders should watch whether the executive team addresses the compensation vote in upcoming earnings calls or proxy materials. The rejection doesn't create immediate operational issues, but it reflects shareholder skepticism that management should monitor, especially if the stock continues to underperform and retention becomes a broader concern beyond non-executive staff.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
REGENXBIO held its 2026 Annual Meeting on May 29, 2026, electing three Class II directors and approving several proposals including auditor ratification.
Added in current filing · verify on EDGAR →
By the following vote, the stockholders approved, the Stock Option Exchange Program for the Company’s non-executive employees: Votes For | Votes Against | Votes Abstaining | Broker Non-Votes | 26,352,456 | 8,853,230 | 59,076 | 7,554,121
Shareholders approved a stock option exchange program for non-executive employees with 26,352,456 votes for versus 8,853,230 against. This program allows non-executive employees to exchange underwater stock options for new options, potentially improving employee retention and morale.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
By the following vote, the following three persons were elected to serve as Class II directors until the Company’s 2029 annual meeting of stockholders: Nominee | Votes For | Votes Withheld | Broker Non-Votes | Jean Bennett, M.D., Ph.D. | 24,025,836 | 11,238,926 | 7,554,121 | A.N. “Jerry” Karabelas, Ph.D. | 27,124,923 | 8,139,839 | 7,554,121 | Daniel Tassé | 32,039,753 | 3,225,009 | 7,554,121
Three Class II directors were elected to serve until the 2029 annual meeting: Jean Bennett, M.D., Ph.D., A.N. "Jerry" Karabelas, Ph.D., and Daniel Tassé. All three nominees received majority support from voting shareholders, with Daniel Tassé receiving the strongest support at 32,039,753 votes for.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 3, 2026, the Company commenced a Stock Option Exchange Program for non-executive employees that was approved by shareholders at the Annual Meeting. The exchange offer period will commence on June 3, 2026 and, unless extended, will conclude on July 1, 2026.
REGENXBIO initiated a shareholder-approved stock option exchange program for non-executive employees running from June 3 through July 1, 2026. This allows eligible employees to exchange underwater stock options for new options, addressing retention concerns when existing options have lost incentive value due to stock price decline.
Added in current filing · verify on EDGAR →
Under the program, eligible participants will be able to exchange outstanding stock options granted under the Company’s 2015 Equity Incentive Plan that have an exercise price at or above $18.00, for a reduced number of stock options at a per share exercise price equal to the fair market value of the Company’s common stock on the grant date of the new options, which is expected to be the first business day following the expiration of the exchange offer.
Employees can exchange options with exercise prices at or above $18.00 for fewer new options priced at current fair market value. The $18.00 threshold indicates the company's stock has traded below this level, making existing options underwater and less effective as retention tools. New options will be priced on the first business day after July 1, 2026.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify